• 제목/요약/키워드: Dose response

검색결과 2,363건 처리시간 0.028초

천연물 항암제제 임상시험 평가지표 개발연구 (Study on Development of Assessment Guideline and Endpoints for Clinical Trial with Antitumor Natural Products)

  • 남궁미애;장유성;정승기;김진성;윤성우;장기영;유화승;정면우;이성호;김성훈
    • 동의생리병리학회지
    • /
    • 제20권6호
    • /
    • pp.1678-1727
    • /
    • 2006
  • This study was perfromed to develop the assessment guideline and endpoints for clinical trial with anticancer herbal medicine. The botanical products used to humans for long time may be applied to phase 3 clinical trial after submitting the evidences for safety and efficacy of them or completion of basic requirement of phase 1 and phase 2 for safety confirmation and dose determination. Syndrome improvement was chiefly evaluated by Zubrod and karnofsky(%) methods. We suggest the general clinical trial assessment with botanical products, by following assessment points, that is, tumor size for 50 points, survival fate for 10 points, major syndromes for 40 points. It is recommendable that the each symptom of Qi deficiency syndrome, blood deficiency syndrome and Qi stagnation syndrome was allocated by assessment points, Similarly, the each symptom was given the assessment points according to the severity of symptom, for example, slight for 3 points, moderate for 2 points and severe for 1 point in hepatocelluar carcinoma and lung cancer. Then, the efficacy of botanical products was evaluated by the difference between pre-treatment and post-treatment. Asking the neoplastic patients of questionnaire on physical, emotional, cognitive, social and role subjects availability, three more syndromes (Fatigue, Pain and Nausea/Vomit), quality of life(QOL) will be evaluated by GLM statistics. In addition, in case of lung cancer, 13 questions will be asked by the EORTC QLQ-C13 forms. As the assessment of endpoints for efficacy to reduce side effects induced by chemotherapy and radiotherapy, the data of image scanning and hemato-urinalysis can be usefully applied on immune response, weight loss, indigestion, hemopoietic damage and injury of liver and kidney, while the changes of syndromes of side effect can be evaluated by differentiation methods of Qi and blood and five viscera. However, it is still necessary to determine the ratio between scientific analytical method and Oriental differentiation method as well as confirm the Oriental assessment endpoints by clinical trial. In addition, we suggest the continuous development of assessment endpoints on other carcinomas except of hepatocelluar carcinoma and lung cancer in future.

진단 X선 검출기 적용을 위한 CdS 센서 제작 및 성능 평가 (The fabrication and evaluation of CdS sensor for diagnostic x-ray detector application)

  • 박지군;이미현;최영준;정봉재;최일홍;강상식
    • 한국방사선학회논문지
    • /
    • 제4권2호
    • /
    • pp.21-25
    • /
    • 2010
  • 최근 진단 X선 검출기 적용을 위한 방사선 검출물질로 반도체 화합물에 대한 많은 연구가 되고 있다. 본 연구에서는 반도체 화합물 중 광민감도가 우수하고 X선 흡수율이 높은 CdS 반도체를 이용하여 검출센서를 제작하였으며, 진단 X선 발생장치에서의 에너지 영역에 대한 검출 특성을 조사함으로써 적용 가능성을 평가하였다. 센서 제작은 CdS 센서로부터의 신호 획득 및 정량화를 위한 Line voltage selector(LCV)를 제작하였으며, 전압감지회로 및 정류회로부를 설계 제작하였다. 또한 X선 노출조건에 따른 상호연과 알고리즘을 이용하였으면, DAC 컨트롤러와의 Interface board를 설계 제작하였다. 성능평가는 X선 발생장치의 조사조건인 관전압, 관전류 및 조사시간별 저항변화에 따른 전압파형 특성을 오실로스코프로 획득하여 ANOVA 프로그램을 이용하여 데이터를 통계 처리 및 분석하였다. 측정결과, 관전압과 관전류이 증가할수록 오차의 비가 감소하였으며, 90kVp에서 6%, 320 mA에서 0.4% 이하의 좋은 특성을 보였으며, 결정계수는 약 0.98로 1:1의 상관관계를 보였다. X선 조사시간에 따른 오차율은 CdS 물질의 늦은 반응속도에 기인하여 조사시간이 길어질수록 지수적으로 감소하는 것을 알 수 있었으며, 320 msec에서 2.3%의 오차율을 보였다. 끝으로 X선 선량에 따른 오차율은 약 10% 이하였으며, 0.9898의 결정계수로 매우 높은 상관관계를 보였다.

Anthracycline계 항암성 항생물질 DA-125의 Beagle dog에 대한 26주 반복정맥투여독성시험 (Toxicity Studies of DA-l25, an Anthracycline Antitumor Antibiotic : Intravenous Repeated Doses for 26 Weeks in Beagle Dogs)

  • 차신우;박종일;정태천;신호철;하창수;김형진;양중익;한상섭;노정구
    • Biomolecules & Therapeutics
    • /
    • 제4권2호
    • /
    • pp.127-137
    • /
    • 1996
  • This study was performed to investigate the toxicity of DA-125 in beagle dogs, an anthracycline antitumor antibiotic. The dogs were administered DA-125 i.v. at 0.0023, 0.0375, 0.15 and 0.6 mg/kg/day, 6 days/week for 26 weeks. At 0.6 mg/kg, all male and female dogs were either sacrificed moribundly or dead during the 26-week treatment. The dogs revealed inactivity, salivation, dark bloody discharge, swelling of the subcutaneous injection site, abscess, and ulceration in the abdominal wall and legs. At 0.15 mg/kg, anorexia, salivation, and swelling of the injection site were observed. The food consumption was decreased with a statistical significance at 6 and 12 weeks treatment in males of 7.6 mg/kg. At 0.0375, 0.15 and 0.6 mg/kg, body weights were decreased significantly in a dose-related fashion after 17 weeks treatment. Total white blood cell counts for male dogs at 0.6 mg/kg were lower than those of control dogs after 13 weeks treatment, which appeared mainly due to decreased neutrophils. At 0.15 mg/kg, testicular atrophy was found in all males by gross pathology and the testicular weights were significantly decreased when compared to those of control males. Microscopically, the testis showed moderate atrophy of the seminiferous tubules and marked decrease in number of spermatozoa in the epididymal tubules. At 0.6 mg/kg, petechia or echymotic hemorrhage was observed in gastrointestinal tract, heart, lungs, and other organs at the necropsy, Marked atrophy of thymus were observed in both males and females. In addition, severe testicular atrophy was noted in all males. Microscopically, gastrointestinal tract showed hemorrhage, epithelial denudation, hypermucus secretion, and atrophy of intestinal villi. Seminiferous tubules of the atrophic testis were lined with Sertoli cells only and devoid of germ cells. Severe oligospermia or aspermia was present in the epididymal tubules. Bone marrow showed marked depletion of hemopoietic cells. In addition, marked atrophy was found in the lymphoid tissue of gastrointestinal tract, various Iymph nodes, and thymus. Injection sites showed marked inflammatory response with necrosis, necrotizing vasculitis, thrombus formation, and ulceration in the skin. According to the present results, no observed effect level appeared to be 0.0375 mg/kg. At 0.15 mg/kg, testis was a target organ, while at 0.6 mg/kg hemopoietic tissue, gastrointestinal tract, and testis were considered to be target organs. At 0.6 mg/kg the test compound seems to inflict a damage on the blood vessels causing hemorrhage in the various organs and tissues.

  • PDF

Dasatinib Inhibits Lyn and Fyn Src-Family Kinases in Mast Cells to Suppress Type I Hypersensitivity in Mice

  • Lee, Dajeong;Park, Young Hwan;Lee, Ji Eon;Kim, Hyuk Soon;Min, Keun Young;Jo, Min Geun;Kim, Hyung Sik;Choi, Wahn Soo;Kim, Young Mi
    • Biomolecules & Therapeutics
    • /
    • 제28권5호
    • /
    • pp.456-464
    • /
    • 2020
  • Mast cells (MCs) are systemically distributed and secrete several allergic mediators such as histamine and leukotrienes to cause type I hypersensitivity. Dasatinib is a type of anti-cancer agent and it has also been reported to inhibit human basophils. However, dasatinib has not been reported for its inhibitory effects on MCs or type I hypersensitivity in mice. In this study, we examined the inhibitory effect of dasatinib on MCs and MC-mediated allergic response in vitro and in vivo. In vitro, dasatinib inhibited the degranulation of MCs by antigen stimulation in a dose-dependent manner (IC50, ~34 nM for RBL-2H3 cells; ~52 nM for BMMCs) without any cytotoxicity. It also suppressed the secretion of inflammatory cytokines IL-4 and TNF-α by antigen stimulation. Furthermore, dasatinib inhibited MC-mediated passive cutaneous anaphylaxis (PCA) in mice (ED50, ~29 mg/kg). Notably, dasatinib significantly suppressed the degranulation of MCs in the ear tissue. As the mechanism of its effect, dasatinib inhibited the activation of Syk and Syk-mediated downstream signaling proteins, LAT, PLCγ1, and three typical MAP kinases (Erk1/2, JNK, and p38), which are essential for the activation of MCs. Interestingly, in vitro tyrosine kinase assay, dasatinib directly inhibited the activities of Lyn and Fyn, the upstream tyrosine kinases of Syk in MCs. Taken together, dasatinib suppresses MCs and PCA in vitro and in vivo through the inhibition of Lyn and Fyn Src-family kinases. Therefore, we suggest the possibility of repositioning the anti-cancer drug dasatinib as a treatment for various MC-mediated type I hypersensitive diseases.

옻 추출물의 세포독성 및 자궁 경부암 바이러스 암 유발인자 E6 와 E7의 작용에 미치는 효과 (The Effects of Rhus Extracts on The Cytotoxicity on Cancer Cells and E6 and E7 Oncogenes of Human Papillomavirus Type 16)

  • 조영식;정옥;조정원;이경애;심정현;김광수;이홍수;성기승;윤도영
    • 한국식품과학회지
    • /
    • 제32권6호
    • /
    • pp.1389-1395
    • /
    • 2000
  • 자궁 경부암은 매년 약 50만명 정도씩 사망하는 여성의 치명적인 사망원인의 하나이다. 인두유종 바이러스(HPV) 16형 및 18형과 자궁 경부암과의 긴밀한 관련성은 잘 알려져 있다. 옻 추출물 Rhus가 HPV 16형의 E6, E7 발암 유전자를 억제하는지 여부를 측정하였다. 이 Rhus는 자궁 경부암 세포주(C-33A, SiHa, Caski)와 HaCaT keratinocytes의 분열은 농도 의존적으로 억제하였다. In vitro binding assay와 효소면역측정법에 의하면 Rhus가 암 억제인자인 p53과 결합하여 분해 시키는데 필수적인 E6와 E6AP와의 결합을 억제할 뿐더러 암 억제인자 Rb와 E7과의 결합을 억제하였다. RT-PCR에 의하면 Rhus에 의해 E6 mRNA의 level이 감소하였으나 E7 mRNA는 변하지 않았음을 보여주었다. 이들 결과에 의하면 Rhus가 HPV 16형의 E6와 E7의 발암성을 억제함을 보여 주므로 HPV에 의해 유도된 자궁 경부암의 치료에 유효할 것으로 사료되어 좀 더 자세한 in vitro실험 등이 요구된다.

  • PDF

여자 청소년 및 젊은 여성의 비타민 D 결핍과 빈혈과의 연관성 분석 (Association between vitamin D deficiency and anemia among Korean adolescent girls and young women)

  • 장하은;박성희;박경
    • Journal of Nutrition and Health
    • /
    • 제52권6호
    • /
    • pp.552-558
    • /
    • 2019
  • 본 연구는 2008 ~ 2014년까지 수행된 국민건강영양조사 자료를 활용하였다. 본 분석 대상자는 12 ~ 29세 여자 청소년 및 젊은 여성이며, 이들을 대상으로 비타민 D 결핍 여부에 따른 빈혈 및 철 결핍성 빈혈과의 연관성 분석을 실시하였다. 그 결과, 교란인자를 보정한 다중 로지스틱 회귀분석 모델에서 비타민 D 결핍군이 충분군보다 빈혈 및 철 결핍성 빈혈의 유병률이 유의적으로 높았다. 또한 혈청 25(OH)D 농도가 증가함에 따라 빈혈 및 철 결핍성 빈혈의 유병률이 낮아지는 선형 관계가 나타났다. 본 연구의 결과는 청소년 및 젊은 여성에서 문제가 되고 있는 비타민 D 결핍과 빈혈에 대한 예방 및 관리에 기초자료를 제공할 수 있다고 기대된다. 추후 전향적인 코호트 연구 및 임상시험 연구 설계를 이용한 후속 연구를 수행하여 비타민 D와 빈혈 사이의 명확한 인과관계를 확인할 필요가 있다고 사료된다.

사염화탄소로 유도된 간 손상에 대한 섬오갈피 추출물의 보호 효과 (Protective effects of Acanthopanax koreanum Kakai extract against carbon tetrachloride-induced liver injury in Sprague-Dawley rats)

  • 양윤경;;권오란
    • Journal of Nutrition and Health
    • /
    • 제47권2호
    • /
    • pp.106-112
    • /
    • 2014
  • 본 연구의 목적은 사염화탄소에 의해 유도된 간독성에 대하여 AE의 항염증 효과와 예방기전을 연구하는 것이다. 사염화탄소에 의해 간손상이 유도된 Sprague-Dawley 쥐에서 간독성 지표, 항염증 및 항산화 활성을 분석하였다. 우선 사염화탄소에 의해 간손상이 유도된 실험동물에서 Acanthopanax koreanum Nakai의 에탄올 추출물 및 acanthoic acid 섭취로 혈장 ALT 활성이 유의하게 개선됨을 보여주었다. 간조직병리학적 분석에서는 사염화탄소 처리된 대조군에서 거대한 브리징 경화와 심각한 지방변성을 관찰하였는데, 이는 사염화탄소에 의해 유도된 간손상이 성공적이었다는 것을 의미한다. 고용량군인 AE3이 저용량군인 AE1보다 간보호 효과가 더 좋은 것으로 보인다. AE는 단일물질인 AA보다 간독성에 대한 예방요인과 항염증 효과로서 중요한 역할을 하는데 더 우세한다. 이러한 결과들을 바탕으로 사염화탄소에 의해 유도된 간손상에 대한 AE와 AA의 예방 효과가 항염증 성질에 부분적으로 관여하는 것을 제안한다. AE의 생화학학적 효과는 단일물질인 AA보다 우수하며 향후 연구에서 식이변경으로 AE에 대한 추가 연구가 더 필요할 것으로 사료된다.

고지방식이를 급여한 비만 마우스에서 luteolin이 화학적으로 유도한 대장암 발생에 미치는 영향 (Effects of luteolin on chemical induced colon carcinogenesis in high fat diet-fed obese mouse)

  • 박정은;김은정
    • Journal of Nutrition and Health
    • /
    • 제51권1호
    • /
    • pp.14-22
    • /
    • 2018
  • 본 연구는 LUT이 고지방식이로 비만이 유도된 C57BL/6 마우스의 대장암 발생에 미치는 영향을 분석하기 위해 실험동물을 각 10마리씩 정상식이 (ND)군, 고지방식이 (HFD)군, HFD + 0.0025% LUT 보충 (HFD LL)군, 그리고 HFD + 0.005% LUT 보충 (HFD HL)군의 4군으로 분류하였다. 각 실험군은 AOM을 1회 복강 주사하고 AOM 투여 1주일 후 총 3 cycle의 1 ~ 2% 농도의 DSS를 음용수로 공급하여 대장암을 유발하였다. 실험식이는 AOM 발암시점부터 총 11주간 급여하였다. 연구결과, 군간 식이섭취량의 차이는 없었으나 HFD 급여군에서 체중과 식이효율의 유의적인 증가가 나타났으며 HFD군과 비교했을 때 LUT 보충에 따른 체중의 변화는 없었다. 그러나 LUT 보충은 ND군에 비해 HFD군에서 나타난 대장 무게/길이 비, 대장종양 수, 혈장 $TNF-{\alpha}$ 농도, 대장 iNOS와 COX-2 발현을 유의적으로 감소시켰으며 그 효과는 HFD HL군이 HFD LL군보다 높았다. 이러한 결과는 체중조절과는 별개로 LUT이 고지방식이에 의한 대장의 염증반응 억제를 통하여 비만과 연관된 대장암 발생을 억제할 수 있음을 제시하며 향후 비만에 의한 인슐린 저항성 및 adipokine 분비, 그리고 장내 균총 변화에 따른 대장 점막세포 증식과 대장암 발생에 LUT이 어떤 영향을 미치는지에 대한 연구를 더 깊이 있게 수행한다면 비만으로 인한 대장암 발생에 LUT이 효과적인 화학적 예방 (chemoprevention)제로 활용될 수 있을 것으로 기대한다.

Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib

  • Kim, Myung Soo;Chung, Ho Seok;Hwang, Eu Chang;Jung, Seung Il;Kwon, Dong Deuk;Hwang, Jun Eul;Bae, Woo Kyun;Park, Jae Young;Jeong, Chang Wook;Kwak, Cheol;Song, Cheryn;Seo, Seong Il;Byun, Seok-Soo;Hong, Sung-Hoo;Chung, Jinsoo
    • Journal of Korean Medical Science
    • /
    • 제33권51호
    • /
    • pp.325.1-325.10
    • /
    • 2018
  • Background: To evaluate survival outcomes and prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who received sunitinib (SU) and pazopanib (PZ) as first-line therapy in real-world Korean clinical practice. Methods: Data of 554 patients with mRCC who received SU or PZ at eight institutions between 2012 and 2016 were retrospectively reviewed. Based on the targeted therapy, the patients were divided into SU (n = 293) or PZ (n = 261) groups, and the clinicopathological variables and survival rates of the two groups were compared. A multivariable Cox proportional hazard model was used to determine the prognostic factors for OS. Results: The median follow-up was 16.4 months (interquartile range, 8.3-31.3). Patients in the PZ group were older, and no significant difference was observed in the performance status (PS) between the two groups. In the SU group, the dose reduction rate was higher and the incidence of grade 3 toxicity was more frequent. The objective response rates were comparable between the two groups (SU, 32.1% vs. PZ, 36.4%). OS did not differ significantly between the two groups (SU, 36.5 months vs. PZ, 40.2 months; log-rank, P = 0.955). Body mass index, Eastern Cooperative Oncology Group PS > 2, synchronous metastasis, poor Heng risk criteria, and liver and bone metastases were associated with a shorter OS. Conclusion: Our real-world data of Korean patients with mRCC suggested that SU and PZ had similar efficacies as first-line therapy for mRCC. However, PZ was better tolerated than SU in Korean patients.

다낭성난소증후군 환자에서 Pioglitazone이 인슐린 민감도, 난소 기능, 난소 기질 내 혈류에 미치는 영향 (Effects of Pioglitazone on Insulin Sensitivity, Ovarian Function and Intraovarian Stromal Blood Flow in Women with Polycystic Ovary Syndrome)

  • 이향아;김정훈;최정원;박선정;이수정;최은선;김성훈;채희동;손영수;강병문
    • Clinical and Experimental Reproductive Medicine
    • /
    • 제32권2호
    • /
    • pp.155-164
    • /
    • 2005
  • Objective: This study was performed to investigate the effects of pioglitazone, an insulin sensitizing agent, on insulin resistance, ovarian function and intraovarian stromal blood flow in patients with polycystic ovarian syndrome (PCOS). Material and Methods: Thirty patients with PCOS, aged 18~34 years, were recruited. Criteria for diagnosis of PCOS were as defined in 2003 Rotterdam consensus. They were treated for 6 months with pioglitazone at a dose of 30 mg/day orally. The hormonal blood profile, fasting serum glucose levels, a glycemic response to 75 g oral glucose tolerance test (OGTT), and an ovarian stromal artery (OSA) blood flow were assessed at baseline and after 6 months of treatment. Results: Eighteen (60.0%) of 30 patients treated with pioglitazone demonstrated a spontaneous ovulation After pioglitazone treatment, fasting insulin concentrations, serum glucose levels after 75 g OGTT significantly decreased (p=0.001, p=0.04, respectively), and fasting glucose to insulin (G/I) ratio significantly increased (p<0.001). The pioglitazone treatment induced a significant reduction in serum LH, testosterone (T) and free T levels (p<0.001, p=0.02, p=0.002, respectively). The resistance index (RI) values of OSA significantly increased after treatment (p<0.001). In analyzing pioglitazone-treated patients according to their body mass index (BMI), nonobese group as well as obese group showed a significant improvement in fasting G/I ratio (p<0.01). The pioglitazone treatment induced a significant reduction in serum LH and free T levels in nonobese group (p<0.001, p<0.05, respectively) as well as obese group (p=0.001, p<0.05, respectively). The RI values of OSA significantly increased in both nonobese and obese groups after pioglitazone treatment (p<0.001, p=0.003, respectively). Conclusions: Pioglitazone could ameliorate the glycoinsulinemic metabolism, and this beneficial effects of this drug could improve the endocrine-reproductive condition associated with the decrease of ovarian stromal artery blood flow, in both nonobese and obese patients with PCOS.